Azithromycin

Producers shown on SFDA

(Record date:25/08/2021）

Producers shown on EP

(Quoted from EP website；record date:25/08/2021）

Producer:Qilu Pharmaceutical is one of the leading vertically integrated pharmaceutical companies in China focusing on the development, manufacturing and marketing of active pharmaceutical ingredients (APIs) & finished formulations. Qilu currently has 12 subsidiaries, 10 manufacturing sites and over 23000 employees worldwide, 70% of whom are with bachelor’s degree or above. It ranks No.8 in Chinese pharmaceutical industry by sales revenue in 2019. Dedicated to offering more affordable medicines to the world and improving people's well-being, Qilu has exported its products to over 70 countries.

Qilu Pharmaceutical has always committed itself to providing high-quality products to patients and the society. The company is the 1st Chinese company to obtain USFDA and EDQM approval for sterile APIs. Its finished formulations and APIs have been approved by USFDA, European Medicines Agency (EMA), Therapeutic Goods Administration (TGA) of Australia, Medicines and Healthcare products Regulatory Agency (MHRA) of UK, PMDA of Japan and other national regulatory authorities.

Staff size:About 8000 persons

Producer:Dyne pharmaceutical, the chairman unit of children's medication Professional Committee of China Pharmaceutical Enterprise Management Association, has always adhered to the corporate mission of "making millions of Chinese children healthy and strong", focusing on the R & D and production of products in the field of children's health.

The company's existing products mainly involve the fields of children's medicine and children's health care and nutritional food, forming a children's health industry layout with "children's health care and treatment field" as the core. The production base in Rongcheng, Shandong Province is designed and arranged in strict accordance with the production standards of professional children's drugs. The dosage forms include granules, dry suspensions, powders, oral liquid preparations, transdermal preparations, topical ointments and suppositories suitable for children. Equipped with world-class production and testing equipment, the production capacity ranks in the forefront of China's children's pharmaceutical industry. The company has established higher than legal internal control standards and strictly controlled the quality of all production links. Two special drug production lines for children have passed the Australian TGA certification and achieved the highest A1 level.

Staff size:About 1500 persons

Registered capital:RMB 62million

Producer:Shanghai Shyndec Pharmaceutical Co.,Ltd, which was established in 1996, is a high-tech enterprise in the pharmaceutical industry which is specialized in manufacturing new drug preparation products and founded by academician of Chinese Academy of Engineering. It was listed on Shanghai stock exchange on June 16, 2004 . In April 2010, it entered China National Pharmaceutical Group Corporation（SINOPHARM）.

In 2016-2017, according to the integration strategy ofSINOPHARM, Shanghai Shyndec Pharmaceutical Co.,Ltd positioned itself as a pharmaceutical industry platform of SINOPHARM, have actively promoted major asset restructuring matters. The main business of the "new Shyndec " wholly-owned or holding subsidiary after the reorganization has achieved nearly 10 billion level of revenue, total profit has exceeded 1 billion yuan, and the number of enterprise members has reached 30, among which 17 are secondary enterprises, 13 are tertiary and four-level enterprises.

After the reorganization, the "New Shyndec" has integrated into many high-quality industrial product lines and enterprise assets of China National Pharmaceutical Group to create a more centralized resource allocation and a clearer main business market. Focusing on the "anti-infection, cardiovascular and cerebrovascular, anti-tumor, leptin drugs, metabolism and endocrine" five areas then has formed and strengthened the "5 + X" industrial chain system with the modern characteristics and core competitiveness of Chinese medicine. The product structure of the company will be richer, the R&D strength will be further strengthened, and the market position of the enterprise has been improved by leaps and bounds.

Staff size:About 600 persons

Registered capital:RMB 1 billion 56 million 226 thousand and 870

Producer:Zhejiang Zhenyuan Pharmaceutical Co., Ltd. is a wholly-owned subsidiary of the Shenzhen listed company "Zhejiang Zhenyuan" and a national key high-tech enterprise. The company has a registered capital of 300 million yuan, covers an area of 345 mu, has more than 900 employees, and about half of them are junior college or above. With a construction area of 120000 square meters, the company has built seven API workshops and two preparation workshops, and has a comprehensive production capacity of API production by chemical synthesis and biological fermentation, oral solid preparations and small volume injections.

Producer:CSPC Ouyi Pharmaceutical Co., Ltd. (formerly Shijiazhuang No. 1 pharmaceutical factory) of CSPC Pharmaceutical Group is a listed enterprise of Shijiazhuang Pharmaceutical Group. It was founded in 1938.
The annual production capacity is: 9 billion tablets, 400 million hard capsules, 400 million soft capsules, 600 million bags of granules, 600 million small volume injections, 300 million powder injections and 200 million bags of dry suspensions.
According to different requirements of customers, the product quality meets BP, USP, JP and EP standards respectively. The company has passed the national GMP quality certification, and the "zero defect project" has passed the FDA certification of the United States and the MCC quality certification of South Africa. Many varieties have obtained the EU CEP certification. It has become the designated manufacturer of well-known purchasers in the Netherlands, Denmark and other countries.

Staff size:4000-4999 persons

Registered capital:RMB 300 million 

Producer:Hainan Star Pharmaceutical Co., Ltd. is a comprehensive pharmaceutical enterprise integrating R & D, production and sales. It is a high-tech enterprise in Hainan Province. The company was established in August 1993. On February 15, 2006, Hainan Sida Pharmaceutical Co., Ltd. was successfully listed on the Singapore Stock Exchange, becoming the first pharmaceutical enterprise listed abroad in Hainan Province.

The company's production base is located in Qionghai City, Hainan Province. It is a garden type drug production base. The plant covers an area of 60000 square meters and has seven dosage form production lines, including powder injection, freeze-dried powder injection, water injection, tablet, capsule and granule. The company has more than 50 kinds of antibacterial, antiviral, cardiovascular and cerebrovascular diseases and other drugs. The whole factory has passed GMP certification.

Staff size:Hong Kong dollar 50 million

Registered capital:Hong Kong dollar 50 million

Producer:HEC Pharmaceutical Co., Ltd. formerly known as HEC Biochemical Pharmaceutical Co., Ltd., was established on January 12, 2004. It is a large-scale western medicine manufacturing and bioengineering enterprise mainly engaged in the R & D, production and sales of macrolide antibiotics, antiviral drugs, insulin and other drugs. At present, the company is the largest in the world It is a manufacturer of macrolide antibiotic API with the most advanced technology. Its main customers are pharmaceutical giants such as Abbott and Pfizer. It is also one of the earliest enterprises engaged in the R & D, registration and production of overseas generic drugs.

The company attaches great importance to the research and development of preparation technology, and has established a variety of preparation technology platforms such as slow and controlled release and transdermal technology. The company is also carrying out the layout of preparation products in Europe and America. At present, seven products have passed the EU cGMP certification, three products have passed the FDA certification, and macrolide APIs have passed the FDA cGMP certification.

Staff size:2000-2999 persons

Registered capital:RMB 813.368 million

Producer:Shaoxing Xingya Pharmaceutical Co., Ltd., established on August 29, 2017, is a wholly-owned subsidiary of Zhejiang Yatai Pharmaceutical Co., Ltd. Zhejiang Asia Pacific Pharmaceutical Co., Ltd. is a professional and large-scale national high-tech enterprise integrating scientific research, production and sales and a key high-tech enterprise of the national torch plan.

Staff size:50-99 persons

Registered capital:RMB 60 million

Producer:Ningxia Qiyuan Pharmaceutical Co., Ltd., established in January 2001, was restructured and merged by the former state-owned enterprise Ningxia pharmaceutical factory and Ningxia traditional Chinese medicine factory. After nearly 20 years of unremitting efforts, the company has developed into a modern large-scale comprehensive biopharmaceutical enterprise well-known at home and abroad. Relying on the regional advantages suitable for the development of biopharmaceutical in Ningxia, the company vigorously develops the R & D and production of antibiotic API, vitamin API and corn deep processing. The company's tetracycline API series products are the exclusive varieties in the world. Erythromycin API and its synthetic products are currently one of the three major suppliers in the world. Vitamin C series products occupy a place in the domestic and foreign markets with their scale and quality.

The company is listed as a national high-tech enterprise, and the company's technology center is a national enterprise technology center. Erythromycin and tetracycline hydrochloride APIs have passed FDA, cos and eugmp certification in Europe, as well as official quality audits in India, Japan and other countries. Vitamin C products of the company have passed international food certification, such as halal, kosher, etc. The company's products are sold to Europe, South America, Africa, Southeast Asia and other dozens of countries and regions.

Staff size:1000-1999 persons

Registered capital:RMB 2.91 million

Producer:Tianjin Biochemical Pharmaceutical Co., Ltd., formerly known as Tianjin biochemical pharmaceutical factory, was founded in 1943. It was one of the three major biochemical drug production bases in China planned by the former State Pharmaceutical Administration. Now it is a modern pharmaceutical enterprise developing and producing biological and chemical drug preparations.

The enterprise moved into the airport economic zone of Tianjin Free Trade Zone at the end of 2005, covering an area of 60 mu, a construction area of 15000 square meters and a total investment of 86 million yuan. The enterprise adopts domestic first-class equipment, complete supporting production facilities, has a research institute and central laboratory, a modern production workshop designed and built according to GMP standards, and seven high standard production lines (including hormones).

Staff size:200-299 persons

Registered capital:RMB 303 million 302 thousand and 800

Producer:Hebei Dongfeng Pharmaceutical Co., Ltd. is a famous modern large pharmaceutical enterprise in China. The API produced has passed the national GMP certification and EU cos certification, and is actively applying for FDA certification. Over the years, relying on strict GMP management, stable product quality and perfect marketing services, various products have been selling well in domestic and foreign markets. At the same time, Dongfeng pharmaceutical has also won a good reputation.

The annual production of doxycycline hydrochloride, the fist product of Dongfeng pharmaceutical, reaches 1000 tons, and the export volume occupies a leading position in the world. The company has increased its investment in azithromycin API, carried out a series of technical innovation and management upgrading, improved the quality day by day, and formed large-scale production, with an annual output of 120 tons. In order to make the products enter the international high-end market, the company has specially purchased the leading testing instruments from the United States, which has reached the quality standard of the 29th edition of the United States Pharmacopoeia.

Staff size:50-99 persons

Registered capital:RMB 50 million

Producer:Hainan Hailing Chemipharma Corporation Limited(Hailing Pharm) is one of the largest pharmaceutical companies integrating pharmaceutical product R&D, production and marketing activities in China.

Founded in 2004 and headquarter at the National High-Tech Industrial Development Zone in Haikou City, Hainan Province, Hailing Pharm is the No. 1 antibiotic manufacturer in China (covers 4,000+ hospitals in China) with existing assets of over 2 billion CNY and more than 600 employees. It occupies 3 modern manufacturing sites (2 DP manufacturing sites, 1 API site) in Haikou and Shanghai respectively.

Hailing Pharm is striving to be an internationalized pharmaceutical company. Our cGMP application for US FDA is under way. We have attempted to expand the global markets since 2017, and we are sparing no effort in exploring global markets.

Staff size:600-699 persons

Registered capital:RMB 116.669422 million

For supply and market information, please feel free to contact Mr. Paul, paulzhang@yinuopharmchem.com, WhatsApp: +86 18402846978